Temporarily Not Available EXPANDED_ACCESS NCT07332338
Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition
Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion for Patients With Post-COVID Condition
Sponsor: StemCyte, Inc.
Conditions
Chronic Fatigue Chronic Fatigue Symptoms Fatigue Post Viral Long COVID Post-COVID Condition Post-COVID Syndrome Post-COVID-19 Condition
Interventions
REGENECYTE®
Updated 1 time since 2026 Last updated: Jan 11, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07332338, this observational or N/A phase trial focuses on Chronic Fatigue and Chronic Fatigue Symptoms and remains ongoing. Sponsored by StemCyte, Inc., it has been updated 1 time since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
1 version recorded Temporarily Not Available
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- StemCyte, Inc.
Data source: StemCyte International, Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.